Rare but Revelatory: Clinical Updates and Research Advances in Uncommon Gynecologic Cancers will provide up-to-date and practical information about treatment as well as presentations about emerging therapeutics and novel regimens. Panel discussions with research leaders and patient advocates will address the challenges of clinical trial design and the unique needs of women with these cancers.

• Moderators: Katie Kurnit, MD & David Gershenson, MD
• NE Tumors of the Cervix – Speaker: M. Frumovitz
• Uterine Serous Carcinoma – Speaker: A. Nickles-Fader
• Germ Cell Tumors – Speaker: L. Frazier
• Low Grade Serous – Speaker: R. Grisham
• Vulvar/Vaginal Melanoma – Speaker: D. Vicus
• Vulvovaginal Melanoma or Vulvar and Vaginal Melanoma: Can These Tumors be Considered The Same? – Speaker: A. Wilhite
• Debate: Should Gynecologic Cancer Trials be Conducted Based on Histology or Molecular Features? (Histology) – Speaker: J. Brown
• Debate: Should Gynecologic Cancer Trials be Conducted Based on Histology or Molecular Features? (Basket) – Speaker: I. Ray-Coquard
• Innovative Biostatistical Designs for Overcoming Logistical Barriers – Speaker: M. Krailo
• Clear Cell Carcinoma/ARID1a/PI3K – Speaker: S. Gaillard & L. Shih
• DNA Methylating Drug Temozolomide Sensitizes ARID1A-Mutated Tumors to PARP Inhibitors – Speaker: T. Wang
• Bridging the Translational Interface in Rare Ovarian Cancers: Endometrioid Ovarian Cancer – Speaker: C. Gourley & R. Hollis
• Ovarian and Uterine Carcinosarcoma Cell Lines Show Preclinical Sensitivity to BAY 1895344, a Novel Ataxia-Telangiectasia and Rad3-related (ATR) Kinase Inhibitor – D. Manavella
• Panel: How to Incorporate TR and Correlative Endpoints – Panelists: K. Kurnit, D. Gershenson, S. Gaillard, L. Shih, T. Wang, C. Gourley, R. Hollis, D. Manavella
• Panel Discussion with Patient Advocates – Panelists: J. Ludemann, K. Richardson, S. Madsen, L. Laughlin

This session was recorded live at the 2022 Annual Meeting on Women's Cancer in March 2022.